Literature DB >> 21647951

Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34+ cell yield.

Hien K Duong1, Brian J Bolwell, Lisa Rybicki, Anna Koo, Eric D Hsi, Priscilla Figueroa, Robert Dean, Brad Pohlman, Matt Kalaycio, Steven Andresen, Ronald Sobecks, Edward Copelan.   

Abstract

Early and reliable prediction of the likelihood of achieving adequate stem cell collection for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM) would improve collection efficiency, prevent unnecessary aphereses, and permit appropriate treatment alterations. No previous study has reported a threshold CD34+ cell collection quantity on Day 1 or 2 of leukapheresis that could predict successful stem cell collection. We performed a retrospective analysis of all MM patients undergoing first attempt of stem cell collection at our institution from 2001 through 2008. Recursive partitioning analysis was used to identify Day 1 or Day 1+2 CD34+ collection quantity that predicted failure to reach target ≥ 2 × 10(6) CD34+ cells/kg within five days of collection. Totally, 172 patients were included in the analysis. Patients underwent mobilization with G-CSF or G-CSF+ chemotherapy. 23 of 172 patients (13.4%) failed to collect sufficient (≥ 2 × 10(6) CD34+ cells/kg) CD34+ cells after five days of apheresis: 22 of 29 who collected ≤ 0.70 × 10(6) CD34+ cells/kg and 1 of 143 who collected > 0.70 × 10(6) CD34+ cells/kg (75.9% vs. 0.7%, P < 0.001) on Day 1. Collection failure occurred in 23 of 30 patients who collected ≤ 1.54 × 10(6) CD34+ cells/kg and 0 of 142 who collected >1.54 × 10(6) CD34+ cells/kg (76.7% vs. 0%, P < 0.001) on Days 1 + 2. Day 1 CD34+ cell collection quantity identifies patients unlikely to achieve adequate collection for ASCT. Patients who collect ≤ 0.70 × 10(6) CD34+ cells/kg on day 1 could be considered for treatment modifications to improve CD34+ collection, such as early administration of plerixafor or large volume apheresis.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21647951     DOI: 10.1002/jca.20278

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  6 in total

Review 1.  Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2011-08-20       Impact factor: 9.546

2.  Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration.

Authors:  M E Horwitz; J P Chute; C Gasparetto; G D Long; C McDonald; A Morris; D A Rizzieri; K M Sullivan; N J Chao
Journal:  Bone Marrow Transplant       Date:  2011-11-14       Impact factor: 5.483

Review 3.  Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.

Authors:  Tim Hartmann; Kai Hübel; Ina Monsef; Andreas Engert; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2015-10-20

Review 4.  Mobilized peripheral blood: an updated perspective.

Authors:  Darja Karpova; Michael P Rettig; John F DiPersio
Journal:  F1000Res       Date:  2019-12-20

5.  Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors.

Authors:  Jingyu Xiang; Min Shi; Mark A Fiala; Feng Gao; Michael P Rettig; Geoffrey L Uy; Mark A Schroeder; Katherine N Weilbaecher; Keith E Stockerl-Goldstein; Shamim Mollah; John F DiPersio
Journal:  Blood Adv       Date:  2022-04-12

6.  Automated dry thawing of cryopreserved haematopoietic cells is not adversely influenced by cryostorage time, patient age or gender.

Authors:  Peter Kilbride; Julie Meneghel; Giovanna Creasey; Fatemeh Masoudzadeh; Tina Drew; Hannah Creasey; David Bloxham; G John Morris; Kevin Jestice
Journal:  PLoS One       Date:  2020-10-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.